Murine Malaria Model: Ketoconazole Prevented Malaria while Proguanil and Sulfadoxine/Pyrimethamine Protected against Malaria-associated Anemia and Kidney Damage

Infect Disord Drug Targets. 2024;24(2):e201023222469. doi: 10.2174/0118715265239831231017080840.

Abstract

Background: The concern about the global spread of resistant malaria has made the researchers not focus only on the treatment of established infections but relatively more on the prevention of the disease.

Objective: This study evaluates the chemopreventive activity of ketoconazole in a murine malarial model.

Method: Five out of seven groups of mice were pretreated for five days with proguanil (PRG), sulfadoxine/ pyrimethamine (SP), 10, 20, and 40 mg/kg body weight (b.w) of ketoconazole (KET10, KET20, and KET40), before being infected (on the sixth day) with Plasmodium berghei. Two other groups were infected-not-treated (INT) and not-infected-nor-treated (NINT). At 72 hours postinfection, five out of ten mice in each group were sacrificed to assess parasitemia, chemoprevention, hematologic, hepatic, and renal parameters. The remaining mice were observed for 28 days to determine their mean survival day post-infection (SDPI).

Results: All ketoconazole groups, except KET10, demonstrated 100% chemoprevention and significantly higher mean SDPI (p<0.001) in relation to INT (negative control). There was no significant difference in the mean SDPI observed in KET20 in relation to PRG or NINT (healthy control). A dose-related increase (p<0.01) in the mean plasma urea was observed when ketoconazole groups were compared to one another: KET10 versus KET20 (p<0.01) and KET20 versus KET40 (p<0.01). Sulfadoxine/pyrimethamine demonstrated significantly reduced mean plasma urea (p<0.001) and creatinine (p<0.05) in relation to INT and NINT, respectively. While PRG demonstrated significantly higher mean red blood cell (RBC), hemoglobin (HGB), and hematocrit (HCT) in relation to INT.

Conclusion: Ketoconazole possesses prophylactic antimalarial activity with associated dose-related renal impairment. Sulfadoxine/pyrimethamine demonstrated renoprotective potentials, while PRG prevented malaria-associated anemia.

Keywords: Malaria; anemia.; ketoconazole; proguanil; renoprotection; renoprotection malaria; sulfadoxine/pyrimethamine.

MeSH terms

  • Anemia* / drug therapy
  • Anemia* / prevention & control
  • Animals
  • Antimalarials* / therapeutic use
  • Ketoconazole / therapeutic use
  • Kidney
  • Malaria* / complications
  • Malaria* / drug therapy
  • Malaria* / prevention & control
  • Malaria, Falciparum*
  • Mice
  • Proguanil / therapeutic use
  • Pyrimethamine / therapeutic use
  • Sulfadoxine / therapeutic use
  • Urea / therapeutic use

Substances

  • Pyrimethamine
  • Proguanil
  • Sulfadoxine
  • Ketoconazole
  • Antimalarials
  • Urea